CN115461365A - 用于治疗幼年特发性关节炎的物质和方法 - Google Patents

用于治疗幼年特发性关节炎的物质和方法 Download PDF

Info

Publication number
CN115461365A
CN115461365A CN202180031397.9A CN202180031397A CN115461365A CN 115461365 A CN115461365 A CN 115461365A CN 202180031397 A CN202180031397 A CN 202180031397A CN 115461365 A CN115461365 A CN 115461365A
Authority
CN
China
Prior art keywords
tnf
antibody
jia
amino acid
tnf antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180031397.9A
Other languages
English (en)
Chinese (zh)
Inventor
K·本斯利
M·克拉克
J·刘
Z·徐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority claimed from PCT/IB2021/053429 external-priority patent/WO2021220140A1/en
Publication of CN115461365A publication Critical patent/CN115461365A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Farming Of Fish And Shellfish (AREA)
CN202180031397.9A 2020-04-27 2021-04-26 用于治疗幼年特发性关节炎的物质和方法 Pending CN115461365A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063015902P 2020-04-27 2020-04-27
US202063015889P 2020-04-27 2020-04-27
US202063015894P 2020-04-27 2020-04-27
US63/015889 2020-04-27
US63/015902 2020-04-27
US63/015894 2020-04-27
PCT/IB2021/053429 WO2021220140A1 (en) 2020-04-27 2021-04-26 Materials and methods for treating juvenile idiopathic arthritis

Publications (1)

Publication Number Publication Date
CN115461365A true CN115461365A (zh) 2022-12-09

Family

ID=78336251

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180031397.9A Pending CN115461365A (zh) 2020-04-27 2021-04-26 用于治疗幼年特发性关节炎的物质和方法

Country Status (9)

Country Link
EP (1) EP4143226A4 (https=)
JP (1) JP2023524668A (https=)
KR (1) KR20230005284A (https=)
CN (1) CN115461365A (https=)
AU (1) AU2021263136A1 (https=)
BR (1) BR112022021766A2 (https=)
CA (1) CA3127807A1 (https=)
IL (1) IL297623A (https=)
MX (1) MX2022013502A (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101500607A (zh) * 2005-05-16 2009-08-05 艾博特生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CN110234351A (zh) * 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101500607A (zh) * 2005-05-16 2009-08-05 艾博特生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CN110234351A (zh) * 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HERMINE I BRUNNER等: "Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomisedwithdrawal trial", 《ANN RHEUM DIS》, vol. 77, no. 1, 15 May 2017 (2017-05-15), pages 21 - 29, XP055868639, DOI: 10.1136/annrheumdis-2016-210456 *
KATE WEBB AND LUCY R. WEDDERBURN: "Advances in the treatment of polyarticular juvenile idiopathic arthritis", 《CURRENT OPINION IN RHEUMATOLOGY》, vol. 27, no. 5, 31 December 2015 (2015-12-31), pages 505 - 510, XP002798373, DOI: 10.1097/BOR.0000000000000206 *
NCT02277444: "A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy", 《CLINICALTRIALS.GOV》, 8 July 2018 (2018-07-08), pages 1 - 13 *

Also Published As

Publication number Publication date
EP4143226A1 (en) 2023-03-08
EP4143226A4 (en) 2024-05-29
MX2022013502A (es) 2023-02-01
CA3127807A1 (en) 2021-10-27
KR20230005284A (ko) 2023-01-09
AU2021263136A1 (en) 2023-01-05
IL297623A (en) 2022-12-01
JP2023524668A (ja) 2023-06-13
BR112022021766A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
JP2022137167A (ja) 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
JP2022133454A (ja) 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
JP2025098055A (ja) 活動性強直性脊椎炎を治療するための抗ｔｎｆ抗体、組成物、及び方法
JP2025157225A (ja) 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
US20210340245A1 (en) Materials and Methods for Treating Juvenile Idiopathic Arthritis
JP7689074B2 (ja) 若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CN115461365A (zh) 用于治疗幼年特发性关节炎的物质和方法
JP2025084901A (ja) 乾癬性関節炎の治療方法で使用するための抗ｔｎｆ抗体組成物
EA052133B1 (ru) Материалы и способы лечения ювенильного идопатического артрита
KR20230121110A (ko) 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물,및 방법
CN116670167A (zh) 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
EA047762B1 (ru) Композиции антитела к фно и способы лечения ювенильного идиопатического артрита
EA051501B1 (ru) Композиции антител к фно для применения в способах лечения псориатического артрита
HK40017724A (en) Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination